CLL
Conference Coverage
Deep remission or long-term control? Choice is key in early CLL
Sequencing therapy in chronic lymphocytic leukemia depends on patient characteristics, prior therapy, frailty, and mutations.
Conference Coverage
M13-982 trial in del(17p) CLL: High, durable response rates to venetoclax
Venetoclax monotherapy is well tolerated and associated with high and durable objective response rates in patients with del(17p) CLL, according to...
From the Journals
Ibrutinib and bleeding complications in Mohs surgery
Temporary discontinuation of ibrutinib might reduce bleeding risks.
Conference Coverage
First-line obinutuzumab monotherapy in CLL linked to good response, reduced toxicity
NEW YORK – Obinutuzumab monotherapy effective for the first-line treatment of chronic lymphocytic leukemia.
Conference Coverage
NF-kB inhibitor IT-901 shows promise in Richter syndrome
In vitro analyses of primary leukemic cells and in vivo analyses in patient-derived xenograft models indicate NF-kB inhibition should be...
Conference Coverage
Telomere length predicts FCR response in CLL patients
NEW YORK – Telomere length reliably predicts response to fludarabine-cyclophosphamide-rituximab (FCR) treatment in patients with chronic...
Conference Coverage
Optimizing therapy in relapsed CLL: ibrutinib and beyond
CHICAGO – The efficacy of ibrutinib is durable for patients with relapsed chronic lymphocytic leukemia (CLL), and combination strategies are...
Conference Coverage
Twofer drug blocks SYK/JAK pathways in advanced NHL
MADRID – Cerdulatinib is an orally dosed agent that inhibits both the Janus kinase (JAK) 1 and 3 pathways and the spleen tyrosine kinase (SYK)...
News
FDA approves rituximab + hyaluronidase human for FL, DLBCL, and CLL
Approval provides patients a subcutaneous route for rituximab, significantly reducing the administration time.
Conference Coverage
Lenalidomide consolidation linked to extended overall survival in non-del(11q) CLL
CHICAGO – Lenalidomide consolidation therapy was associated with an extended survival plateau for patients with non-del(11q) chronic lymphocytic...
Conference Coverage
Sequential triple therapy produces high response rates in CLL
“Sequential triple-T” (tailored and targeted treatment) aimed at complete eradication of MRD looks promising for CLL.